For HRD patients, we proposed potential therapies to overcome the treatment challenges posed by PARPi resistance and the limited clinical benefit achieved by PARPi and anti‐PDCD1 combination therapy. Here, PDCD1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.